<DOC>
	<DOCNO>NCT00215943</DOCNO>
	<brief_summary>Investigators plan accrue 176 participant , compare response rate , overall response rate survival patient multiple myeloma ( MM ) randomize two regimen ( thalidomide+Dexamethasone versus Vincristine+Adriamycin+Dexamethasone ) . Investigators also plan test treatment zoledronate immediately prior chemotherapy result enhance response treatment ( i.e . increase complete response rate ) .</brief_summary>
	<brief_title>Phase III Randomized Trial Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone ( VAD )</brief_title>
	<detailed_description>Patients Randomized receive VAD ( vincristine , adriamycin , dexamethasone ) : All patient receive four cycle VAD repeat every 4 week . Chemotherapy administer continuous IV Infusion 96 hour : vincristine dose 0.4 mg/day doxorubicin dose 9 mg/m^2/day . Patients administer dexamethasone 40 mg mouth ( PO ) day 1 4 , 9 12 , 17 20 initial two cycle . Dexamethasone give day 1-4 subsequent cycle . Patients randomize receive zoledronic acid IV either Day 1 15 cycle . This schedule continue monthly long patient remain study . The dose calculate base patient ' monthly creatinine clearance . Upon initiation Zometa therapy , follow guideline apply : For patient creatinine clearance &gt; 60 mL/min , recommend dose remain 4mg . For patient reduced creatinine clearance , dose calculate achieve area curve ( AUC ) patient creatinine clearance 75 mL/min . Creatinine clearance calculate use Cockcroft-Gault formula .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients must newly diagnose MM confirm presence bone marrow plasmacytosis &gt; 10 percent plasma cell , sheet plasma cell , biopsyproven plasmacytoma . Patients must DurieSalmon Stage IIAB IIIAB . Patients nonsecretory myeloma eligible . ( These patient include analysis response rate , assessed toxicity survival ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 , 3 ≥ 18 year age . Signed informed consent form Expected survival great 8 week Capable swallow study medication tablet Capable follow direction regard take study medication , daily care provider responsible administer study medication . Patients eligible study even lack socioeconomic access autologous transplantation . ( These patient identify prior randomization confound study result ) . All patient ( event randomize thalidomide/dexamethasone arm ) must agree take part `` System Education Prescribing Safety '' ( S.T.E.P.S. ) ™ . They must sign separate informed consent program . Elevated direct bilirubin &gt; 2 mg/dl Serum alanine aminotransferase ( ALT ) serum aspartate aminotransferase ( AST ) &gt; 2 time upper limit normal ( ULN ) Absolute neutrophil count ( ANC ) &lt; 1000/mL , unless felt secondary myeloma Ongoing radiation therapy , radiation therapy within 3 week prior first treatment , unless acute side effect associate therapy resolve . Prior treatment multiple myeloma Prior bisphosphonate use allow must discontinue start treatment . Concurrent uncontrolled serious infection Patients peripheral ( sensory ) neuropathy , grade 3 high Lifethreatening illness ( unrelated tumor ) History ACTIVE INVASIVE cancer present condition ( except nonmelanoma skin cancer ) , unless complete remission therapy disease minimum 3 year . Women childbearing potential ( unless utilize birth control ) pregnant nursing exclude study . Patients comorbid condition would contraindicate use vincristine , doxorubicin , dexamethasone , thalidomide , zoledronate . Plasma Cell Leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>hematologic malignancy</keyword>
</DOC>